retatrutide clinical trials results trial information phase approval: FDA status, results, and when it could be available Do not obsess over Retatrutide. – New Retatrutide Phase 3 Trial – Lilly's 'triple G' agonist triumphs

Another study found that GLP-1 agonists are associated with a lower risk of major adverse kidney events and death from cardiovascular causes in people with type 2 diabetes and chronic kidney disease

After 24 weeks of treatment: people taking Farxiga 5 mg had their fasting blood sugar* levels decreased by 24.1 mg/dL and their hemoglobin A1c (A1C) level was lowered by 0.8%, on average people taking Farxiga 10 mg had their fasting blood sugar levels decreased by 28.8 mg/dL and their A1C level lowered by 0.9%, on average people taking the placebo had their fasting blood sugar levels decreased by 4.1 mg/dL and their A1C level lowered by 0.2%, on average About 44% to 51% of people in this study who took Farxiga for 24 weeks reached their goal A1C of less than 7%

10.1177/20458940211006289 30 Fadon-PadillaL.de AlejoC.M.-P.Miguel-CoelloA

Check with your insurance provider for coverage details

Medical and Cosmetic Procedures for Skin Lightening Skin-lightening treatments can go beyond creams and include medical or cosmetic procedures